Mars Men Raises $27.5M Series A from L Catterton for Men's Wellness

Mars Men, a men's wellness brand built around hormonal health optimization, closed a $27.5 million Series A round led by L Catterton, the consumer-focused private equity firm backed by LVMH. The funding marks one of the larger early-stage raises in the men's wellness category this year — a segment that's attracted growing investor attention as brands move beyond traditional supplements into condition-specific products targeting testosterone, stress, and metabolic health.

The round comes as Mars Men transitions from a primarily direct-to-consumer operation into retail partnerships and broader product development. Founded three years ago, the brand has built a customer base around products designed for men experiencing hormonal shifts, fatigue, and age-related wellness challenges — positioning itself in the gap between clinical interventions and generic multivitamins.

L Catterton's involvement signals institutional validation for a market that's been fragmented and underserved relative to women's wellness. The firm has a track record in consumer health, having backed brands like Vita Coco, Cholula, and skincare line Beautycounter. Its bet on Mars Men suggests a thesis that men's wellness — long dominated by bodybuilding supplements and generics — is ready for a premiumization wave similar to what reshaped women's health products over the past decade.

Mars Men plans to deploy the capital across three priorities: expanding into national retail chains, launching new product lines beyond its core testosterone-support supplements, and building out clinical validation for its formulations. The company declined to disclose revenue figures but said its customer base has grown 300% year-over-year since launch, with repeat purchase rates above 60%.

The men's wellness market has lagged behind women's in both product innovation and brand development. While women's health has seen an explosion of condition-specific solutions — from menstrual care to menopause support — men's health products have remained largely generic, dominated by protein powders and basic multivitamins. Mars Men is part of a new cohort attempting to change that.

L Catterton's interest reflects a broader shift. Men's testosterone levels have been declining across populations for decades, sparking mainstream conversation about hormonal health that extends beyond fitness enthusiasts. Prescription testosterone replacement therapy has grown into a multi-billion-dollar market, but a gap exists for over-the-counter solutions targeting men who don't meet clinical thresholds for hormone therapy but still experience symptoms like low energy, mood changes, and reduced libido.

Mars Men targets that middle ground. Its flagship product line focuses on herbal and nutrient-based formulations — ashwagandha, fenugreek, zinc, vitamin D — marketed with clinical language but sold without prescriptions. The brand positions itself as science-backed without the clinical baggage of medical intervention, appealing to men who want optimization without the stigma or commitment of testosterone injections.

The company also benefits from demographic tailwinds. Millennial and Gen X men are more willing than prior generations to engage with wellness products and discuss health issues openly. That shift has created space for brands to talk about topics — stress, hormonal balance, mental clarity — that were once considered either too clinical or too personal for consumer marketing.

Mars Men launched as a direct-to-consumer brand, relying on digital advertising and influencer partnerships to build initial traction. That model worked for customer acquisition and brand building but comes with limitations. DTC margins compress as customer acquisition costs rise, and scale requires physical retail presence — especially for a product category where purchase decisions often happen in-store.

The Series A funding will finance retail expansion, with Mars Men planning placements in national chains like CVS, Walgreens, and Target over the next 18 months. Retail distribution introduces new challenges: lower per-unit margins, slotting fees, inventory risk, and competition for shelf space in a crowded supplement aisle. But it also offers access to customers who don't buy wellness products online and provides credibility that comes from physical presence.

The company's retail strategy focuses on the men's health section — a category that's been expanding in pharmacy chains as retailers recognize demand for condition-specific products. Mars Men will compete with established brands like GNC's testosterone boosters and newer entrants like Onnit, which has built distribution through its parent company Unilever's retail relationships.

Success in retail will depend on differentiation. Mars Men emphasizes branding — minimalist packaging, clinical-but-accessible language, and marketing that avoids the hyperbolic claims common in men's supplements. The bet is that a premium brand built on transparency and efficacy can command higher price points and customer loyalty in a category historically driven by price and promises of dramatic results.

Beyond testosterone support, Mars Men plans to launch products targeting sleep, cognitive function, and metabolic health — all categories where men's-specific products remain underdeveloped. The company sees opportunity in creating a portfolio that addresses interconnected health issues rather than selling single-purpose supplements.

That approach mirrors successful women's wellness brands like Ritual and Care/of, which built loyalty by offering personalized or condition-specific product bundles rather than standalone supplements. Mars Men's repeat purchase rate suggests customers are open to a multi-product relationship, and expanding the catalog could increase lifetime value while reducing dependence on a single SKU.

The company is also exploring partnerships with men's health clinics and telemedicine platforms — distribution channels that offer access to customers already engaged with hormonal health but looking for alternatives to prescription treatments. Those partnerships could provide both revenue and clinical credibility, positioning Mars Men as a bridge between self-care and medical intervention.

Mars Men's competitive landscape includes both supplement brands and telehealth platforms. While companies like Roman and Hims focus on prescription products, Mars Men occupies the over-the-counter segment — lower barriers to purchase but also less clinical differentiation and more retail competition.

Part of the Series A funding will support clinical studies on Mars Men's formulations. The supplement industry is largely unregulated beyond basic safety requirements, and efficacy claims often rely on individual ingredient studies rather than testing of proprietary blends. Mars Men is investing in its own clinical trials — a costly and time-intensive process that few DTC supplement brands undertake.

L Catterton has been active in consumer wellness, but its portfolio has historically leaned toward food, beverage, and beauty. Mars Men represents a deeper push into functional health products — a category the firm has signaled interest in as wellness and medical products converge.

The firm's involvement brings more than capital. L Catterton operates a platform approach, connecting portfolio companies with operational resources, retail relationships, and category expertise. For Mars Men, that could mean faster retail onboarding, introductions to ingredient suppliers, and access to L Catterton's network of brand operators who've scaled DTC businesses into omnichannel giants.

L Catterton's backing also positions Mars Men for a potential exit within 3-5 years. The firm typically seeks liquidity through strategic sales to larger consumer or pharmaceutical companies. In men's wellness, potential acquirers include major supplement brands looking to enter condition-specific categories, pharmaceutical companies seeking OTC adjacencies, or retail chains building owned brands in health.

The firm declined to disclose the post-money valuation or ownership stake taken in the round. Mars Men's existing investors, including early-stage VCs and angel investors from the wellness and consumer sectors, participated in the round but did not lead.

The Series A follows a wave of funding into men's health startups over the past three years. Hims went public via SPAC in 2021 at a $1.6 billion valuation and now trades at roughly $2.8 billion. Ro, which operates Roman, raised a $150 million Series D in 2023 at a reported $5 billion valuation. Those companies focus on prescription products and telemedicine, making them less direct comparables to Mars Men's OTC model.

Closer analogues include companies like Momentous, a supplement brand focused on performance and longevity, which raised $20 million in 2023, and Thesis, a nootropics brand targeting cognitive function, which raised $13 million in 2022. Mars Men's $27.5 million raise suggests investor appetite for men's wellness is scaling beyond early-stage checks into growth capital.

The supplement industry's light regulatory environment is both advantage and risk. Brands can bring products to market quickly without FDA approval, but they also face scrutiny over efficacy claims and potential regulatory crackdowns. The FTC has increased enforcement against supplement companies making unsubstantiated health claims, and Mars Men will need to navigate marketing language carefully as it scales.

There's also competitive pressure from commoditization. Many of Mars Men's ingredients — zinc, vitamin D, ashwagandha — are widely available in generic supplements at lower price points. The brand's ability to command premium pricing depends on differentiation through formulation, branding, and customer experience. If customers don't perceive meaningful differences, they'll trade down to cheaper alternatives.

Customer acquisition costs in wellness are rising as digital advertising becomes more expensive and saturated. Mars Men will need to prove that its unit economics work at scale, especially as it moves into retail where margins compress. The 60% repeat purchase rate is promising, but sustaining that as the customer base broadens will be critical.

Retail placement also carries execution risk. Shelf space is finite, and retailers increasingly favor owned brands with higher margins. Mars Men will compete not just with other third-party brands but with CVS Health's and Walgreens' private label products, which benefit from prime placement and retailer incentives.

The efficacy of testosterone-boosting supplements remains contested. While ingredients like ashwagandha and fenugreek have some clinical support for hormonal effects, studies are often small, short-term, or industry-funded. The magnitude of effect is typically modest — far less than prescription testosterone — and individual variation is high.

Mars Men's planned clinical trials could provide differentiation if results are positive and published in peer-reviewed journals. But clinical validation is expensive and slow, and there's no guarantee outcomes will support marketing claims. If trials fail to show meaningful effects, the brand risks undermining its science-backed positioning.

The women's wellness market offers a potential roadmap. Over the past decade, brands like Goop, Ritual, and The Honey Pot Co. built businesses by identifying underserved conditions, creating premium products, and marketing with a mix of clinical credibility and lifestyle positioning. Many were acquired by larger consumer or pharmaceutical companies — Procter & Gamble bought This Is L., Unilever bought Olly and Onnit, and Nestlé invested in personalized nutrition platforms.

If men's wellness follows a similar trajectory, Mars Men is well-positioned. It's entered early in a category that's fragmented and under-branded, secured institutional capital from a strategic investor, and is building infrastructure for omnichannel scale. The question is whether men will engage with wellness products at the same rate and willingness to pay premiums that women have shown.

Cultural shifts suggest the answer may be yes. Men's mental health, body image, and wellness have become mainstream conversation topics in ways they weren't a decade ago. Podcasts, influencers, and athletes openly discuss hormonal health, optimization, and self-care — language that was previously gendered as feminine or dismissed as vanity. That shift creates market opportunity, but it also invites competition as larger brands notice the trend.

Mars Men's raise is among the largest Series A rounds in men's wellness over the past two years, signaling both investor confidence and the capital requirements for scaling a consumer health brand in a competitive market.

The company's near-term success will hinge on retail execution and customer retention as it moves beyond early adopters into a broader market. Longer-term, the brand's ability to sustain differentiation in a category prone to commoditization will determine whether it becomes a durable player or a cautionary tale of overfunded hype in wellness.

Mars Men's next 18 months will be telling. Retail placement announcements will signal execution capability, and revenue growth will indicate whether the brand can convert DTC success into physical store performance. Customer acquisition costs in the retail channel typically differ significantly from digital, and the company's ability to maintain margins while scaling will be scrutinized.

Product launches beyond testosterone support will test whether Mars Men can build a portfolio brand or remains a single-category player. Expansion into sleep, cognitive function, and metabolic health will face competition from established brands in each vertical — Nature Made in sleep aids, Onnit and Thesis in nootropics, and dozens of brands in metabolic health.

L Catterton's playbook suggests Mars Men is likely being groomed for an exit within 3-5 years. Potential acquirers include large pharmaceutical companies looking to enter consumer wellness, major supplement brands seeking to premiumize their portfolios, or retail chains building owned brands in men's health. A successful exit would validate the broader thesis that men's wellness is entering a consolidation phase similar to what women's health experienced in the mid-2010s.

The market will also be watching whether clinical trials produce publishable results and whether those results translate into marketing differentiation. If Mars Men can demonstrate efficacy that competitors can't claim, it gains a defensible advantage. If trials disappoint, the brand loses a key pillar of its positioning and risks becoming just another supplement with nice branding.